Barclays Maintains Overweight on Medline, Lowers Price Target to $43
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.